LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1302)

VOLUNTARY ANNOUNCEMENT

Admission to Special Examination and Approval Procedure for Innovative Medical Devices in respect of Artery Stent Graft System

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that on 27 January 2021, the Company obtained formal written notice from the National Medical Products Administration ("**NMPA**") confirming the admission of Artery Stent Graft System (the "**Product**") into NMPA Special Examination and Approval Procedure for Innovative Medical Services (藥監局創新醫療器械特別審查程序) (the "**Procedure**"). The Product is the 13th product of the Company having obtained admission to the Procedure.

The Product consists of the Ankura™ Pro Artery Stent Graft System ("**Ankura™ Pro**") and Longuette™ Aortic Branch Stent Graft System ("**Longuette™ Skirt Stent**"). It is the world's first stent graft system adopted "chimney technology" and is developed to treat aortic dissection lesion involving the aortic arch. Ankura ™ Pro has the ability to resist swelling and offers a variety of tapers, making it appropriate for patients with acute and subacute aortic dissections. The Longuette™ Skirt Stent adopts a segmented design concept. The proximal end of the segmented stent provides a large radial support force. When used with the main stent, it can maintain a shape to facilitate smooth blood flow in the branch blood vessels. The distal end of the segmented stent has higher compliance and smaller radial support force which can adapt to various distorted branch blood vessels of various anatomical shapes.

The Product possesses independent intellectual property rights and a number of international patents. It is expected to provide a complete, safe and effective endovascular repair solution for the treatment of aortic dissection lesion involving the aortic arch, which is completely interventional with the expected benefits of causing less trauma, being simpler to operate and easier to acclimatize.

The Board believes that the admission of the Product into the Procedure will shorten the registration process of the Product, whereby expediting its launching process. It is expected that the launching of the Product will benefit patients suffering from aortic dissection lesion involving the aortic arch while enriching the Group's product portfolio and fostering the Group's development in medical devices.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman
and Chief Executive Officer

Hong Kong, 27 January 2021

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive directors; Mr. JIANG Feng and Mr. FU Feng being non-executive directors; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive directors.